Literature DB >> 30655259

Utility of Dynamic Susceptibility Contrast Perfusion-Weighted MR Imaging and 11C-Methionine PET/CT for Differentiation of Tumor Recurrence from Radiation Injury in Patients with High-Grade Gliomas.

Z Qiao1, X Zhao1, K Wang1, Y Zhang1, D Fan1, T Yu2,3, H Shen4, Q Chen1, L Ai5.   

Abstract

BACKGROUND AND
PURPOSE: Both 11C-methionine PET/CT and DSC-PWI could be used to differentiate radiation injury from recurrent brain tumors. Our aim was to assess the performance of MET PET/CT and DSC-PWI for differentiation of recurrence and radiation injury in patients with high-grade gliomas and to quantitatively analyze the diagnostic values of PET and PWI parameters.
MATERIALS AND METHODS: Forty-two patients with high-grade gliomas were enrolled in this study. The final diagnosis was determined by histopathologic analysis or clinical follow-up. PWI and PET parameters were recorded and compared between patients with recurrence and those with radiation injury using Student t tests. Receiver operating characteristic and logistic regression analyses were used to determine the diagnostic performance of each parameter.
RESULTS: The final diagnosis was recurrence in 33 patients and radiation injury in 9. PET/CT showed a patient-based sensitivity and specificity of 0.909 and 0.556, respectively, while PWI showed values of 0.667 and 0.778, respectively. The maximum standardized uptake value, mean standardized uptake value, tumor-to-background maximum standardized uptake value, and mean relative CBV were significantly higher for patients with recurrence than for patients with radiation injury. All these parameters showed a high discriminative power in receiver operating characteristic analysis. The optimal cutoff values for the tumor-to-background maximum standardized uptake value and mean relative CBV were 1.85 and 1.83, respectively, and corresponding sensitivities and specificities for the diagnosis of recurrence were 0.97 and 0.667 and 0.788 and 0.88, respectively. Areas under the curve for the tumor-to-background maximum standardized uptake value and mean relative CBV were 0.847 ± 0.077 and 0.845 ± 0.078, respectively. Combined assessment of the tumor-to-background maximum standardized uptake value and mean relative CBV showed the largest area under the curve (0.953 ± 0.031), with corresponding sensitivity and specificity of 0.848 and 1.0, respectively.
CONCLUSIONS: Both 11C-methionine PET/CT and PWI are equally accurate in the differentiation of recurrence from radiation injury in patients with high-grade gliomas, and a combination of the 2 modalities could result in increased diagnostic accuracy.
© 2019 by American Journal of Neuroradiology.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30655259     DOI: 10.3174/ajnr.A5952

Source DB:  PubMed          Journal:  AJNR Am J Neuroradiol        ISSN: 0195-6108            Impact factor:   3.825


  9 in total

Review 1.  Clinical Imaging for Diagnostic Challenges in the Management of Gliomas: A Review.

Authors:  Alipi V Bonm; Reed Ritterbusch; Patrick Throckmorton; Jerome J Graber
Journal:  J Neuroimaging       Date:  2020-01-10       Impact factor: 2.486

2.  Diagnostic yield of simultaneous dynamic contrast-enhanced magnetic resonance perfusion measurements and [18F]FET PET in patients with suspected recurrent anaplastic astrocytoma and glioblastoma.

Authors:  Otto M Henriksen; Adam E Hansen; Aida Muhic; Lisbeth Marner; Karine Madsen; Søren Møller; Benedikte Hasselbalch; Michael J Lundemann; David Scheie; Jane Skjøth-Rasmussen; Hans S Poulsen; Vibeke A Larsen; Henrik B W Larsson; Ian Law
Journal:  Eur J Nucl Med Mol Imaging       Date:  2022-07-30       Impact factor: 10.057

Review 3.  The Utility of Conventional Amino Acid PET Radiotracers in the Evaluation of Glioma Recurrence also in Comparison with MRI.

Authors:  Giulia Santo; Riccardo Laudicella; Flavia Linguanti; Anna Giulia Nappi; Elisabetta Abenavoli; Vittoria Vergura; Giuseppe Rubini; Roberto Sciagrà; Gaspare Arnone; Orazio Schillaci; Fabio Minutoli; Sergio Baldari; Natale Quartuccio; Sotirios Bisdas
Journal:  Diagnostics (Basel)       Date:  2022-03-29

Review 4.  Diagnostic Performance of PET and Perfusion-Weighted Imaging in Differentiating Tumor Recurrence or Progression from Radiation Necrosis in Posttreatment Gliomas: A Review of Literature.

Authors:  N Soni; M Ora; N Mohindra; Y Menda; G Bathla
Journal:  AJNR Am J Neuroradiol       Date:  2020-08-27       Impact factor: 3.825

Review 5.  Hemodynamic Imaging in Cerebral Diffuse Glioma-Part B: Molecular Correlates, Treatment Effect Monitoring, Prognosis, and Future Directions.

Authors:  Vittorio Stumpo; Lelio Guida; Jacopo Bellomo; Christiaan Hendrik Bas Van Niftrik; Martina Sebök; Moncef Berhouma; Andrea Bink; Michael Weller; Zsolt Kulcsar; Luca Regli; Jorn Fierstra
Journal:  Cancers (Basel)       Date:  2022-03-05       Impact factor: 6.639

6.  Perfusion magnetic resonance imaging in the differentiation between glioma recurrence and pseudoprogression: a systematic review, meta-analysis and meta-regression.

Authors:  Jun Zhang; Yulin Wang; Yan Wang; Huafeng Xiao; Xinjing Chen; Yifei Lei; Zhebin Feng; Xiaodong Ma; Lin Ma
Journal:  Quant Imaging Med Surg       Date:  2022-10

Review 7.  Research progress on mechanism and imaging of temporal lobe injury induced by radiotherapy for head and neck cancer.

Authors:  Zhuangzhuang Zheng; Bin Wang; Qin Zhao; Yuyu Zhang; Jinlong Wei; Lingbin Meng; Ying Xin; Xin Jiang
Journal:  Eur Radiol       Date:  2021-07-29       Impact factor: 5.315

8.  Evaluation of perfusion MRI value for tumor progression assessment after glioma radiotherapy: A systematic review and meta-analysis.

Authors:  Longlong Wang; Lizhou Wei; Jingjian Wang; Na Li; Yanzhong Gao; Hongge Ma; Xinran Qu; Ming Zhang
Journal:  Medicine (Baltimore)       Date:  2020-12-24       Impact factor: 1.817

9.  Diagnostic Accuracy of PET for Differentiating True Glioma Progression From Post Treatment-Related Changes: A Systematic Review and Meta-Analysis.

Authors:  Meng Cui; Rocío Isabel Zorrilla-Veloz; Jian Hu; Bing Guan; Xiaodong Ma
Journal:  Front Neurol       Date:  2021-05-20       Impact factor: 4.003

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.